Merck and GSK need to overcome cultural barriers to cervical cancer vaccine roll-out

June 22, 2006

Merck and GlaxoSmithKline (GSK) need to identify the cultural, as well as economic, barriers to the roll-out of their cervical cancer vaccines if countries are to benefit from the drugs without delay, states an Editorial in this week's issue of The Lancet.

Gardasil--Merck's vaccine against cervical cancer--approved by the US Food and Drug Administration (FDA) earlier this month, should save lives in both developed and developing countries. But social and cultural resistance to the product may hamper effective roll-out, states the Editorial. The introduction of Gardasil in the USA is already proving problematic because adolescents need to receive the vaccine before they become sexually active for it to be effective. This means they would need to be taught about sex at the same time. Some believe sex education at this age would undermine abstinence education, and encourage inappropriate sexual activity at a young age.

The Bill and Melinda Gates Foundation announced on June 5 that it will give US$27.7 million to PATH--the programme for appropriate technologies in health--to fund research on how best to introduce the new HPV vaccine into developing countries. The Lancet believes that Merck and GSK can assist in this work and help smooth the introduction of the new vaccine in both developing and rich nations alike.

The Lancet concludes: "Merck and GlaxoSmithKline--whose own vaccine Cervarix is expected to be submitted for FDA approval this year--therefore have an unique opportunity. By working with PATH to identify cultural, as well as economic, barriers to vaccine roll-out, these companies have the chance to show that enlightened self-interest is a policy position not reserved for governments alone. "
-end-
Contact: The Lancet press office T) +44 (0) 207424 4949/4249 pressoffice@lancet.com

Lancet

Related Cervical Cancer Articles from Brightsurf:

HPV strains may impact cervical cancer prognosis
An analysis of cervical cancers in Ugandan women has uncovered significant genomic differences between tumours caused by different strains of human papillomavirus (HPV), signifying HPV type may impact cervical cancer characteristics and prognosis.

American Cancer Society updates guideline for cervical cancer screening
An updated cervical cancer screening guideline from the American Cancer Society reflects the rapidly changing landscape of cervical cancer prevention in the United States, calling for less and more simplified screening.

Disasters can affect cervical cancer screening for years
Screening is important for the early detection of cervical cancer, but rates were significantly affected, in some areas for years, following a devastating earthquake and tsunami in Japan.

Cervical cancer elimination possible within two decades in the US
At current levels of screening and HPV vaccination, cervical cancer incidence in the US is projected to fall below the threshold of elimination by 2038-2046.

Cervical cancer screening saves lives
Three-year interval in screening for cervical cancer is as effective as annual checkups, study finds.

Cervical cancer could be eliminated within a century
Cervical cancer could be eliminated worldwide as a public health issue within the next century.

25 years of learning to combat cervical cancer
A recent paper from the lab of Professor Sudhir Krishna at the National Centre for Biological Sciences, Bangalore, reviews the progress made in cervical cancer research over the past 25 years.

Cervical cancer screening numbers drop off in women 45-65
Virtually all cervical cancers are caused by HPV, and much of the attention in recent years has focused on preventing infections in younger women through HPV vaccination.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cost-effectiveness analysis of 12 cervical cancer screenings
This cost-effectiveness analysis incorporates women's preferences and estimates quality of life and economic outcomes for 12 cervical cancer screening strategies.

Read More: Cervical Cancer News and Cervical Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.